Thrombelastogram for evaluating perioperative blood clot changes in patients received rivaroxaban anticoagulation after hip revision surgery
返回论文页
|更新时间:2023-12-22
|
Thrombelastogram for evaluating perioperative blood clot changes in patients received rivaroxaban anticoagulation after hip revision surgery
Journal of Chongqing Medical UniversityVol. 45, Issue 8, (2020)
作者机构:
1. 重庆医科大学附属第一医院骨科,重庆,400016
2. 重庆市大足区人民医院骨科,重庆,400900
作者简介:
基金信息:
DOI:
CLC:
Published:2020,
扫 描 看 全 文
Yang Jianye, Zhu Sizheng, Qin Leilei, et al. Thrombelastogram for evaluating perioperative blood clot changes in patients received rivaroxaban anticoagulation after hip revision surgery. [J]. Journal of Chongqing Medical University 45(8).(2020)
DOI:
Yang Jianye, Zhu Sizheng, Qin Leilei, et al. Thrombelastogram for evaluating perioperative blood clot changes in patients received rivaroxaban anticoagulation after hip revision surgery. [J]. Journal of Chongqing Medical University 45(8).(2020)DOI:
Thrombelastogram for evaluating perioperative blood clot changes in patients received rivaroxaban anticoagulation after hip revision surgery
Objective:To assess the coagulation function changes by using thrombelastogram(TEG) in patients receiving rivaroxaban anticoagulation after hip revision surgery. Methods:Data of 75 patients underwent hip revision from April 2014 to December 2017 were reviewed. All patients took rivaroxaban of 10 mg within 12 hours after surgery to prevent thrombus with the frequency of once a day. All patients received TEG determination before surgery and on the 1st,3nd,5th and 7th day after surgery. Changes of TEG pa-rameters and proportional difference of hypercoagulable states at different time were compared. Results:Reaction time(R) on the 1st,3nd,5th and 7th day after surgery was decreased than that before surgery,with statistically significant difference. Mean clot index (CI) on the 1st,3nd,5th and 7th day after surgery was increased than that before surgery,with statistically significant difference. Mean maximum amplitude(MA) on the 5th and 7th day after surgery was increased than that before surgery,with statistically significant dif-ference. A total of 34.67% patients had hypercoagulable states on the 7th day,with the main of mixed hypercoagulability. Conclusion:The conventional dose of rivaroxaban is used for anticoagulation after hip revision,but the patient is still in a hypercoagulable state,with the main of mixed hypercoagulability. The existing thromboprophylaxis program after hip revision may be not perfect,therefore,exploring the individualized anticoagulation program is the future research direction.